Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
February 18, 2026 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
February 18, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

We are pleased with advancements made with our R&D programs and... our lead asset PRP which we are preparing for our world-first, Phase 1b, clinical study
February 17, 2026 07:18 ET | Source: ICPO Foundation

Prof. Lalith Kumar Shiyam Sundar, LMU Klinikum München, erhielt den ICPO Research Grant für „KI-gestützte Fortschritte in der Präzisionsonkologie“

Sein Projekt wird von der ICPO Foundation mit 100.000 Euro gefördert und wurde aus 18 hochkarätigen Bewerbungen aus zwölf Ländern ausgewählt. 17. Februar 2026 – Wiesbaden, Deutschland. Die...
February 17, 2026 07:18 ET | Source: ICPO Foundation

Prof. Lalith Kumar Shiyam Sundar, LMU Hospital Munich, received the ICPO Research Grant for “AI-driven Advancements in Precision Oncology”

Prof. Lalith Kumar Shiyam Sundar, LMU Hospital Munich, received the Research Grant for “AI-driven Advancements in Precision Oncology” from ICPO Foundation
February 15, 2026 08:08 ET | Source: Crosetto Foundation for the Reduction of Cancer Deaths

SCIENTIFICALLY UNREFUTED: A Breakthrough Invention Saving Millions of Lives and Billions of Dollars Awaits a Public Comparative Evaluation Within CPRIT’s $6 Billion Cancer Program

Crosetto’s 3D-CBS can detect tumors with <100 cancer cells at €200, 2-min safe whole-body test with the potential to save >260 lives/device/year
February 12, 2026 16:35 ET | Source: AIM ImmunoTech Inc.

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on...
February 12, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer ...
February 12, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
February 12, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP Announces Appointment of David Horn to Board of Directors

EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic...